<DOC>
	<DOC>NCT02788006</DOC>
	<brief_summary>Multicenter prospective phase II study evaluating regorafenib in older patients with metastatic colorectal cancer</brief_summary>
	<brief_title>Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Metastatic colorectal cancer with histological proof Measurable disease according RECIST 1.1 Age ≥ 70 years ECOG ≤ 1 Biological values Haemoglobin ≥ 9 g/dL, PNN ≥ 1500/mm3, platelets≥ 100 000/mm3, bilirubin ≤ 1,5N, ASAT, ALAT et PAL ≤ 2,5N (≤ 5N if hepatic metastases), lipase ≤1,5N, TP≥ 70%, Creatinine clairance ≥ 30 mL/min Patient without response to 5FU chemotherapy or antivegf treatment or anti EGFR treatment (if RAS wildtype), in progression during this treatment or treatment stopped because of toxicities Geriatric Questionnaires answered Lifeexpectancy ≥ 3 months Informed Consent Signed Not able to swallow tablets (crushed tablets are not allowed) Previous treatment with regorafenib or other multikinase treatment Other cancer during the last 5 years, excepted insitu cervix cancer, skin cancer non melanoma and cancer of the bladder curatively treated Radiotherapy: with extended fields in the last 4 weeks, with limited fields in the last 2 weeks previous inclusion Toxicity &gt; grade 1 not resolved with previous treatment Major surgery in the 28 days before the inclusion Non cicatrized injury, ulcer or bone fracture Congestive Cardiac insufficiency classe &gt;2 (NYHA) Unstable angor in the last 3 months Myocardial Infraction in the 6 months before inclusion HTA not controlled Pheochromocytome Arterial or venous thromboembolism in the past 6 months Infection of grade &gt; 2 VIH infection B or C hepatitis necessiting a specific treatment Cirrhosis Suspicion of brain metastasis or brain metastasis Haemorraghe ofgrade &gt;3 in the last weeks Symptomatic Pulmonary fibrosis Proteinuria &gt; grade 3 Malabsorption Allergy know to the treatment or to one similar treatment or to one treatment component Systemic anticancer drug during the study or the the last 4 weeks Concomitant treatment with CYP3A4 inhibitor or inductor or with UGT1A9 inhibitor Social, psychological or medical condition which can interfere with the study participation</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>